MigreLief Blog

To receive a current coupon…
enter your email address below and one will be emailed to you (new signups only).
For those already signed up for the MigreLief newsletter,
look for email from Akeso Health Sciences for the latest coupon offers.
(Don’t forget to check your spam folder if you don’t see it in your inbox)

Sign Up Today!

Email Address:

Enter coupon codes at checkout when ordering online at MigreLief.com
or call 1-800-758-8746 to order by phone.
May not combine with other offers or specials. One coupon per order. Orders of 3 bottles or more qualify for FREE worldwide shipping.

All of us at Akeso Health Sciences would like to wish our MigreLief fans, both patients and health care professionals a wonderful and migraine free Thanksgiving. We are thankful that MigreLief is making a difference in your life and we appreciate the stories you have shared and the gratitude you have expressed.

Many of you have told us you “pay it forward” by telling other migraine sufferers about MigreLief and we are truly grateful. Your wonderful feedback fuels our efforts to empower as many migraine sufferers as possible with our nutritional option for battling this debilitating disorder.

We especially appreciate those who have helped us spread the word about Children’s MigreLief for kids age 2 through 11 who suffer chronic migraines. Children do not have many options when it comes to migraine control. We recently attended the Child Neurology Conference in Vancouver, BC and the American Academy of Pediatrics conference in San Francisco and were pleased to discover so many healthcare professionals recommending both Children’s MigreLief (daily maintenance) and MigreLief-NOW (acute) for their young patients.

Thank you for placing your trust in MigreLief. We wish you a very happy Thanksgiving and a wonderful holiday season.

To the Best of Health,

Curt Hendrix, M.S., C.C.N., C.N.S. and the MigreLief Team at Akeso Health Sciences

Last month, Akeso Health Sciences attended annual conferences of the AAP (American Association of Pediatricians) and the CNS (Child Neurology Society) to exhibit its migraine supplements as effective nutritional support for children aged 2+ suffering either chronic or episodic migraine.

It was great to meet face to face with some of the neurologists, headache specialists and other healthcare professionals who have been recommending MigreLief supplements for years. Both MigreLief formulas, “daily maintenance” and “as-needed” were well received.
It was at the recent CNS convention that we were first informed of the study regarding the use of topiramate and amitriptyline for migraine prevention in children. The study was published simultaneously with its presentation at the annual meeting of the Child Neurology Society in Vancouver.

A randomized, double-blind, placebo-controlled trial of 328 children and adolescents aged 8-17 who were diagnosed with migraines (with our without aura) concluded that amitriptyline and topiramate proved no better than placebo at preventing migraine in children and were associated with adverse side-effects.

In the study, the participants recorded the number of headaches they experienced during a 28 day baseline period and then were given either a placebo, topiramate, or amitriptyline during a 24 week trial period. The drug doses were increased every 2 weeks over an 8 week period with doses modified according to side-effects. In the end, no differences in effectiveness were seen between the two drug groups and the placebo group, however, the authors observed higher rates of adverse side-effects overall in the active treatment groups than the placebo.

Amitriptyline users more often reported fatigue (30%) and dry mouth (25%), whereas topiramate users more often reported parathesia (31%) (burning or prickling sensation that is usually felt in the hands, arms, legs, or feet, but can also occur in other parts of the body), and weight loss (8%). Other side-effects reported with topirimate included, fatigue (25%), dry mouth (18%), memory impairment (17%), aphasia (16%), cognitive disorder (16%), and upper respiratory tract infection (12%). Serious adverse events included altered mood in three patients in the amitriptyine group and one suicide attempt in the topiramate group.

Before the trial was concluded, the Food and Drug Administration approved topiramate for the treatment of episodic migraine in adolescents aged 12-17 years.

“Given the null outcome in this trial and the adverse events and serious adverse events reported in the amitriptyline and topiramate groups, the data do not show a favorable risk-benefit profile for the use of these therapies in pediatric migraine prevention, at least over the 24-week duration of the trial,” the study authors concluded.

If you are a parent of a young migraine sufferer, consider MigreLief nutritional migraine supplements.

phone: (800) 758-8746 | email: sales@akesohealth.com
* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.